217730 — Kang Stem Biotech Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Kang Stem Biotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9,138	12,405	16,301	5,913	7,746
Cost of Revenue
Gross Profit	1,046	2,689	4,873	2,483	4,325
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	29,527	35,127	36,652	25,571	22,490
Operating Profit	-20,389	-22,722	-20,351	-19,658	-14,744
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-19,756	-21,811	-20,215	-19,306	-7,083
Provision for Income Taxes
Net Income After Taxes	-19,746	-21,827	-20,176	-19,306	-7,083
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-18,471	-21,348	-20,236	-21,949	-7,669
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-18,471	-21,348	-20,236	-21,949	-7,669
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-507	-592	-399	-382	-104
Dividends per Share